Hcw biologics announces positive results of studies of proprietary compound, hcw9206 and availability for commercialization

Addresses key challenges for car-t therapies potential to significantly reduce costs and improve clinical efficacy of engineered effector t cells data shared at 2025 annual meeting of american association of immunologists miramar, fla., may 13, 2025 (globe newswire) -- hcw biologics inc. (“hcwb” or the “company”) (nasdaq: hcwb), a u.s.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today presentation of studies showing that its proprietary fusion protein, hcw9206, provides a new pathway for generating chimeric t-cell receptor - t cells (car-ts) for immunotherapy with increased function.
HCWB Ratings Summary
HCWB Quant Ranking